company background image
603079 logo

Zhejiang Shengda Bio-Pharm SHSE:603079 Stock Report

Last Price

CN¥14.21

Market Cap

CN¥2.4b

7D

-13.1%

1Y

-2.5%

Updated

28 Dec, 2024

Data

Company Financials

Zhejiang Shengda Bio-Pharm Co., Ltd.

SHSE:603079 Stock Report

Market Cap: CN¥2.4b

603079 Stock Overview

Develops, produces, and sells food and feed additives for pharmaceutical, nutritional, food, and animal feed industry. More details

603079 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Zhejiang Shengda Bio-Pharm Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Zhejiang Shengda Bio-Pharm
Historical stock prices
Current Share PriceCN¥14.21
52 Week HighCN¥21.21
52 Week LowCN¥7.01
Beta0.42
1 Month Change-5.39%
3 Month Change24.65%
1 Year Change-2.47%
3 Year Change-17.86%
5 Year Change-48.11%
Change since IPO28.17%

Recent News & Updates

Subdued Growth No Barrier To Zhejiang Shengda Bio-Pharm Co., Ltd. (SHSE:603079) With Shares Advancing 28%

Oct 28
Subdued Growth No Barrier To Zhejiang Shengda Bio-Pharm Co., Ltd. (SHSE:603079) With Shares Advancing 28%

What Zhejiang Shengda Bio-Pharm Co., Ltd.'s (SHSE:603079) 27% Share Price Gain Is Not Telling You

Aug 08
What Zhejiang Shengda Bio-Pharm Co., Ltd.'s (SHSE:603079) 27% Share Price Gain Is Not Telling You

Recent updates

Subdued Growth No Barrier To Zhejiang Shengda Bio-Pharm Co., Ltd. (SHSE:603079) With Shares Advancing 28%

Oct 28
Subdued Growth No Barrier To Zhejiang Shengda Bio-Pharm Co., Ltd. (SHSE:603079) With Shares Advancing 28%

What Zhejiang Shengda Bio-Pharm Co., Ltd.'s (SHSE:603079) 27% Share Price Gain Is Not Telling You

Aug 08
What Zhejiang Shengda Bio-Pharm Co., Ltd.'s (SHSE:603079) 27% Share Price Gain Is Not Telling You

Revenues Working Against Zhejiang Shengda Bio-Pharm Co., Ltd.'s (SHSE:603079) Share Price Following 26% Dive

Jun 12
Revenues Working Against Zhejiang Shengda Bio-Pharm Co., Ltd.'s (SHSE:603079) Share Price Following 26% Dive

Zhejiang Shengda Bio-Pharm Co., Ltd.'s (SHSE:603079) 30% Dip In Price Shows Sentiment Is Matching Revenues

Apr 25
Zhejiang Shengda Bio-Pharm Co., Ltd.'s (SHSE:603079) 30% Dip In Price Shows Sentiment Is Matching Revenues

Zhejiang Shengda Bio-Pharm Co., Ltd. (SHSE:603079) Surges 31% Yet Its Low P/S Is No Reason For Excitement

Mar 08
Zhejiang Shengda Bio-Pharm Co., Ltd. (SHSE:603079) Surges 31% Yet Its Low P/S Is No Reason For Excitement

Shareholder Returns

603079CN PharmaceuticalsCN Market
7D-13.1%-1.9%-0.6%
1Y-2.5%-5.7%8.3%

Return vs Industry: 603079 exceeded the CN Pharmaceuticals industry which returned -5.7% over the past year.

Return vs Market: 603079 underperformed the CN Market which returned 8.3% over the past year.

Price Volatility

Is 603079's price volatile compared to industry and market?
603079 volatility
603079 Average Weekly Movement10.1%
Pharmaceuticals Industry Average Movement7.3%
Market Average Movement8.7%
10% most volatile stocks in CN Market12.9%
10% least volatile stocks in CN Market5.6%

Stable Share Price: 603079 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: 603079's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a1,032Bin Zhouwww.sd-pharm.com

Zhejiang Shengda Bio-Pharm Co., Ltd. develops, produces, and sells food and feed additives for pharmaceutical, nutritional, food, and animal feed industry. It offers vitamins, such as biotin and folic acid; biological preservatives, including nisin and natamycin; and intermediate APIs. The company is based in Tiantai, China.

Zhejiang Shengda Bio-Pharm Co., Ltd. Fundamentals Summary

How do Zhejiang Shengda Bio-Pharm's earnings and revenue compare to its market cap?
603079 fundamental statistics
Market capCN¥2.41b
Earnings (TTM)-CN¥28.70m
Revenue (TTM)CN¥792.17m

3.0x

P/S Ratio

-83.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
603079 income statement (TTM)
RevenueCN¥792.17m
Cost of RevenueCN¥690.58m
Gross ProfitCN¥101.59m
Other ExpensesCN¥130.29m
Earnings-CN¥28.70m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Apr 28, 2025

Earnings per share (EPS)-0.17
Gross Margin12.82%
Net Profit Margin-3.62%
Debt/Equity Ratio18.8%

How did 603079 perform over the long term?

See historical performance and comparison

Dividends

0.4%

Current Dividend Yield

-33%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/28 03:04
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Zhejiang Shengda Bio-Pharm Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution